Tau Inhibitors Pipeline Insight

DelveInsight’s, “Tau Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Tau Inhibitors  pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Geography Covered

• Global coverage

 

Tau Inhibitors: Understanding

Tau Inhibitors: Overview

Tauopathy is a class of neurodegenerative conditions that are associated with pathological phosphorylated tau protein accumulation in the human brain. Tauopathy has been associated with several clinicopathological conditions, including chronic traumatic encephalopathy (CTE), traumatic brain injuries, post-traumatic stress disorder, and Alzheimer’s disease (AD).

In humans, tau is encoded by a single gene on chromosome 17q21 containing 16 exons. Alternative splicing of exons 2, 3 and 10 allows for six tau isoforms with 352–441 amino acids, differing from each other by the presence of zero, one or two inserts (0 N, 1 N and 2 N) in its amino-terminal part and three or four microtubule-binding domains (3R or 4R) in its carboxy-terminal part. Tau is subject to a host of post-translational modifications, including phosphorylation, acetylation, ubiquitination, SUMOylation, glycosylation, nitration, methylation, prolyl-isomerization, glycation and truncation. Tau is abundant in axons, where it binds to microtubules, although it is also found in the neuron’s soma and dendrites at lower levels. Under normal conditions, tau is mainly involved in microtubule assembly and stabilization and contributes to the regulation of intracellular trafficking.

Microtubule-associated protein tau is characterized by the fact that it is an intrinsically disordered protein due to its lack of a stable conformation and high flexibility. Intracellular inclusions of fibrillar forms of tau with a β-sheet structure accumulate in the brain of patients with Alzheimer's disease and other tauopathies. Accordingly, detachment of tau from microtubules and transition of tau from a disordered state to an abnormally aggregated state are essential events preceding the onset of tau-related diseases. Animal and pathological studies using human samples have demonstrated that tau oligomer formation contributes to neuronal loss. During the progression of tauopathies, tau seeds are released from cells and incorporated into other cells, leading to the propagation of pathological tau aggregation.

In addition to traditional low-molecular-weight compounds, newer drug discovery approaches such as the development of medium-molecular-weight drugs (peptide- or oligonucleotide-based drugs) and high-molecular-weight drugs (antibody-based drugs) provide alternative pathways to preventing the formation of abnormal tau. Tau-targeted drugs may be a promising disease-modifying therapy because previous studies focusing on the correlation of AD neuropathological changes (Aβ plaques and NFT) with cognitive impairment have shown that the severity of cognitive impairment correlated best with the burden of abnormal tau.

 

“Tau Inhibitors - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Tau Inhibitors pipeline landscape is provided which includes the disease overview and Tau Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Tau Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tau Inhibitors  collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Tau Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Tau Inhibitors.

 

Tau Inhibitors Emerging Drugs Chapters

This segment of the Tau Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Tau Inhibitors Emerging Drugs

• BEY2153: BeyondBio Inc.

BEY-2153 is an investigational drug developed by BeyondBio for the treatment of Alzheimer's disease (AD). It employs a dual mechanism of action as an amyloid-beta protein (AB) inhibitor and tau protein inhibitor, targeting two key pathological hallmarks of AD simultaneously. Preclinical studies demonstrated that BEY-2153 reduces neuronal death and improves cognitive and behavioral functions in animal models. Currently the drug is in Phase II stage of its clinical trial for the treatment of Alzheimer's disease.

 

• Bepranemab: UCB Biopharma

Bepranemab (UCB0107) is an investigational, humanized IgG4 monoclonal antibody developed by UCB Biopharma. It specifically targets a central region of the tau protein (amino acids 235–250), which is believed to play a key role in tau aggregation and neurodegeneration in Alzheimer’s disease (AD). Bepranemab binds to the mid-region of tau, aiming to inhibit the cell-to-cell spread of pathological tau aggregates, a process implicated in AD progression. The drug is in the Phase II stage of development for the treatment of Alzheimer’s disease.

 

• LY3954068: Eli Lilly and Company

LY3954068 (also known as MAPT siRNA) is an investigational small interfering RNA (siRNA) therapeutic developed by Eli Lilly and Company for the treatment of Alzheimer's disease. LY3954068 targets and reduces the production of tau protein in the brain using RNA interference technology. It is currently in Phase I stage of development for the treatment of Alzheimer Disease.

Further product details are provided in the report……..

 

Tau Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Tau Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Tau Inhibitors

There are approx. 15+ key companies which are developing the therapies for Tau Inhibitors. The companies which have their Tau Inhibitors drug candidates in the most advanced stage, i.e. Registered Phase include, TauRx Therapeutics.

 

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Tau Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Tau Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tau Inhibitors therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tau Inhibitors drugs.

 

Tau Inhibitors Report Insights

• Tau Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Tau Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tau Inhibitors drugs?
• How many Tau Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tau Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tau Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tau Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?